Phase II study of sequential methotrexate-5-FU therapy in advanced measurable colorectal cancer.
Eighteen patients with previously untreated advanced colorectal cancer were treated with a sequential methotrexate-5-FU regimen. One of 16 evaluable patients achieved a partial response. The results of this and other clinical and laboratory investigations reported to date suggest that further study of different doses and schedules of sequential methotrexate-5-FU is warranted.